A UK start-up is preparing a groundbreaking experiment to start early next year in eight European countries for 400 patients with treatment-resistant depression.
The company will use psilocybin and digital technology to follow up if it gains approval from the European Medicines Agency and other regulators.
There has been more and more interest over the years in the potential use of the magic mushroom chemical to assuage the effects of severe depression.
